News
Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...
Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...
Skye Bioscience nears Phase IIa data for nimacimab, targeting obesity treatment gaps with robust preclinical insights.
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
8h
GlobalData on MSNMounjaro and Zepbound fuel strong Q2 growth for Eli LillyEli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
First ever daily Ozempic-like PILL helps users shed up to 2st – and could be available within months
A DAILY weight loss pill that works like Ozempic can help users shed an average of almost two stone, a study reveals. People ...
For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...
The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...
Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results